A Phase 1B/2 Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 (RICOLINOSTAT) in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Trial Profile

A Phase 1B/2 Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 (RICOLINOSTAT) in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Ricolinostat (Primary) ; Dexamethasone; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Acetylon Pharmaceuticals; Celgene Corporation
  • Most Recent Events

    • 31 Aug 2017 Planned End Date changed from 15 Sep 2019 to 31 May 2019.
    • 31 Aug 2017 Planned primary completion date changed from 15 Jun 2019 to 28 Feb 2019.
    • 12 Jun 2017 Planned End Date changed from 31 Dec 2018 to 15 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top